IONS
Ionis Pharmaceuticals Inc
NASDAQ: IONS · HEALTHCARE · BIOTECHNOLOGY
$74.83
+4.25% today
Updated 2026-04-29
Market cap
$11.85B
P/E ratio
—
P/S ratio
12.56x
EPS (TTM)
$-2.38
Dividend yield
—
52W range
$30 – $87
Volume
2.2M
WallStSmart proprietary scores
21
out of 100
Grade: F
Strong Sell
Investment rating
4.0
Growth
C5.3
Quality
C+2.0
Profitability
F5.7
Valuation
C+4/9
Piotroski F-Score
Moderate
—
Altman Z-Score
—
—
Industry rank
—
View all highly rated stocks (75+) →200 stocks currently score above 75
Price targets
Analyst target
$98.74
+31.95%
12-Month target
—
—
Intrinsic (DCF)
$154.06
Margin of safety
+45.25%
6 Strong Buy10 Buy6 Hold0 Sell0 Strong Sell
Price chart
X-Ray snapshot
Strengths
+ 45.25% below intrinsic value
Risks
- Altman Z 0.00 — distress zone
- Thin margins at -40.40%
- Negative free cash flow $-159.00M
- Revenue declining -10.30% QoQ
Key financials
Revenue Net Income Free Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Revenue | $587.37M | $787.65M | $705.14M | $944.00M | $943.71M |
| Net income | $-269.72M | $-366.29M | $-453.90M | $-381.00M | $-229.00M |
| EPS | — | — | — | — | $-2.38 |
| Free cash flow | $-294.47M | $-335.52M | $-546.23M | $-320.03M | $-159.00M |
| Profit margin | -45.92% | -46.50% | -64.37% | -40.36% | -40.40% |
Recent insider activity
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| 2026-04-16 | JENNE, KYLE | Sale | 4,902 | $75.17 |
| 2026-04-16 | BIRCHLER, BRIAN | Sale | 973 | $75.04 |
| 2026-04-16 | BAROLDI, JOSEPH | Sale | 5,619 | $74.56 |
Peer comparison
Smart narrative
Ionis Pharmaceuticals Inc trades at $74.83. Our Smart Value Score of 21/100 indicates the stock is weak. The company scores 4/9 on the Piotroski F-Score. TTM revenue stands at $943.71M. with profit margins at -40.40%. Our DCF model estimates intrinsic value at $154.06.
Frequently asked questions
What is Ionis Pharmaceuticals Inc's stock price?
Ionis Pharmaceuticals Inc (IONS) trades at $74.83.
Is Ionis Pharmaceuticals Inc overvalued?
Smart Value Score 21/100 (Grade F, Strong Sell). DCF value $154.06.
What is the price target of Ionis Pharmaceuticals Inc (IONS)?
The analyst target price is $98.74, representing +32.0% upside from the current price of $74.83.
What is the intrinsic value of Ionis Pharmaceuticals Inc (IONS)?
Based on our DCF model, intrinsic value is $154.06, a +45.3% margin of safety versus $74.83.
What is Ionis Pharmaceuticals Inc's revenue?
TTM revenue is $943.71M.
Piotroski F-Score?
4/9 — moderate financial health.
Company info
SectorHEALTHCARE
IndustryBIOTECHNOLOGY
CountryUSA
ExchangeNASDAQ
CurrencyUSD
Quick metrics
P/S ratio12.56x
ROE-70.80%
Beta0.40
50D MA$75.74
200D MA$69.21
Shares out0.17B
Float0.16B
Short ratio—
Avg volume2.2M
Performance
1 week+1.00%
1 month-0.35%
3 months-10.79%
YTD-5.41%
1 year—
3 years—
5 years—